Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05518578 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
A Phase 2 study, sponsored by Supernus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT05518578: Recruiting Phase 2 study, sponsored by Supernus Pharmaceuticals.
NCT05518578 is a Phase 2 study that is actively recruiting participants, run by Supernus Pharmaceuticals. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05518578, a Phase 2 study, is actively recruiting participants, sponsored by Supernus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures
Primary Outcome
The incidence of adverse events.
Interventions
- DRUG SPN-817
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-02-07 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT05518578 shows while recruiting
NCT05518578 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 1 intervention - of which SPN-817 is the first listed.
NCT05518578 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05518578 about?
NCT05518578 is a clinical study titled "Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy". This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures
What is the current status of trial NCT05518578?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-02-07. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT05518578?
The interventions under investigation include: SPN-817 (DRUG).
Who is sponsoring clinical trial NCT05518578?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05518578's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI